Clinical Trial

Memantine as an Additive Therapy in Patients With Traumatic Brain Injury

Not Yet Recruiting Phase 2/3
View on ClinicalTrials.gov →
Record status
This record was last updated April 6, 2025 (before its estimated August 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
Memantine has shown promise in mitigating secondary brain injury in previous studies. One study demonstrated that early memantine administration in moderate TBI patients resulted in lower serum neuron-specific enolase levels and improved Glasgow Coma Scale scores. However, other trials investigating memantine's impact on long-term cognitive function in TBI patients have yielded mixed results. There is a need for well-controlled studies to determine the efficacy of memantine in improving neurological and cognitive outcomes in patients with TBI.
Trial Details
NCT Number NCT06914310
Lead Sponsor Mansoura University
Conditions Mild Traumatic Brain Injury, Moderate Traumatic Brain Injury (TBI)
Enrollment 80 participants
Start Date 2025-03-25
Primary Completion 2025-08-30 (estimated)
Study Completion 2025-11-30 (estimated)
Updated on ClinicalTrials.gov 2025-04-06